In Minimally-Invasive Heart Valves, Edwards Cuts a Wide Swath
Executive Summary
Heart valves used in surgical procedures constitute more than 40% of the revenues of Edwards Lifesciences. So the company's recent acquisition of endovascular heart valve company Percutaneous Valve Technologies Inc. (PVT), along with its earlier acquisition of a percutaneous heart valve from Jomed NV, could be regarded as part of its plan to launch a pre-emptive strike. Edwards now has the broadest and most advanced portfolio of endovascular heart valve repair products in the industry. It thus hedges itself against the possible future erosion of its surgical valve franchise by the new interventional cardiology-oriented approaches and beats out Medtronic and Boston Scientific, each of which previously held 10% stakes in PVT before the acquisition.
You may also be interested in...
Evalve: Leading the Valve Revolution
Full-scale commercialization of percutaneous heart valve technology is still years away, but Evalve's new approach to mitral repair is closest to the clinic.
Edwards: Battling the Innovator's Dilemma
Having built a franchise serving cardiac surgeon, Edwards is looking to maintain its market leadership by both expanding into peripherals and embracing interventionalists.
Edwards: Battling the Innovator's Dilemma
Having built a franchise serving cardiac surgeon, Edwards is looking to maintain its market leadership by both expanding into peripherals and embracing interventionalists.